PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
-30.37%
Negative gross profit growth while AGEN is at 9.64%. Joel Greenblatt would examine cost competitiveness or demand decline.
-24.83%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-24.83%
Negative operating income growth while AGEN is at 6.55%. Joel Greenblatt would press for urgent turnaround measures.
-17.79%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-12.12%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-9.09%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
5.06%
Share count expansion well above AGEN's 4.90%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.04%
Diluted share count expanding well above AGEN's 3.55%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-120.47%
Negative OCF growth while AGEN is at 25.92%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-120.93%
Negative FCF growth while AGEN is at 22.61%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-252.09%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
90.56%
5Y OCF/share CAGR above 1.5x AGEN's 57.13%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
77.71%
3Y OCF/share CAGR above 1.5x AGEN's 44.42%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
99.67%
Positive 10Y CAGR while AGEN is negative. John Neff might see a substantial advantage in bottom-line trajectory.
85.97%
5Y net income/share CAGR above 1.5x AGEN's 29.79%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
69.72%
3Y net income/share CAGR above 1.5x AGEN's 21.64%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
173.45%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-62.01%
Negative 5Y equity/share growth while AGEN is at 86.24%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
56.61%
3Y equity/share CAGR at 50-75% of AGEN's 95.10%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.09%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-13.24%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-1.77%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
45.24%
R&D dropping or stable vs. AGEN's 139.80%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-4.95%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.